Praj Industries partners with IATA and ISMA to develop India-specific carbon certification for SAF
Praj Industries has signed a strategic Memorandum of Understanding (MoU) with the International Air Transport Association (IATA) and the Indian Sugar & Bio-energy Manufacturers Association (ISMA) to advance carbon assessment and certification for Sustainable Aviation Fuel (SAF) in India. This tripartite partnership aims to conduct a Life Cycle Assessment (LCA) of sugarcane-derived SAF via the Ethanol-to-Jet (ETJ) pathway, aligning it with global sustainability benchmarks like ISCC and RSB CORSIA.
The collaboration marks a major milestone toward India's goal of achieving a 1% SAF blending mandate by 2027 and 2% by 2028. The agreement will determine the carbon intensity of domestically produced SAF and develop certification standards tailored for India.
Praj Industries, a pioneer in India's bio-economy space, already operates India's first integrated SAF demo plant and has produced SAF in partnership with Indian Oil and AirAsia India. This initiative aligns with the government's vision of green aviation infrastructure, highlighted by Prime Minister Modi during the 81st IATA AGM.
Commenting on the partnership, Dr. Pramod Chaudhari, Founder Chairman of Praj Industries, stated that the MoU ensures India's SAF development meets the highest global standards. ISMA's Director General added that this is a demonstration of India's sugar industry's potential to become a leading SAF supplier in Asia.
This effort underscores India's growing role in sustainable aviation and supports global decarbonization goals through indigenous innovation and certification frameworks.
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
9 hours ago
- Medscape
New Tool Guides Blood Cancer Txs For Patients 60+
TOPLINE: A novel Comprehensive Health Assessment Risk Model (CHARM) incorporating seven health variables effectively predicts nonrelapse mortality and survival in allogeneic hematopoietic cell transplantation recipients aged at least 60 years. The model stratified 1-year nonrelapse mortality rates from 8.1% to 23.3% across risk groups, outperforming traditional assessment methods. METHODOLOGY: A multicenter (n = 49), prospective, observational clinical trial enrolled 1105 recipients of allogeneic hematopoietic cell transplantation aged ≥ 60 years (range, 60-82 years) from centers across the US. Researchers analyzed associations between 13 measurements of older adult health and nonrelapse mortality within 1 year to construct a comprehensive health assessment risk model using multivariate Fine-Gray model and grouped penalized variable selection. Analysis included two machine learning models (Cox and pseudo-value boosting) for comparison, with performance evaluated using area under the curve, bootstrap and cross-validation sampling, decision curve analysis, calibration, and Brier scores. Primary outcome measure was 1-year nonrelapse mortality, defined as death without relapse or progression of primary hematologic malignancy. TAKEAWAY: Primary-CHARM identified seven key predictors: higher comorbidity burden, C-reactive protein, weight loss, and age, along with lower albumin, patient-reported performance score, and cognitive score (hazard ratio [HR], 2.72; P < .0001). Patients in low, intermediate, and high CHARM score tertiles showed 1-year nonrelapse mortality rates of 8.1% (95% CI, 5.6-11.1), 12.1% (95% CI, 9.1-15.7), and 23.3% (95% CI, 19.0-27.7), respectively. Overall survival at 1 year was 71.7% (95% CI, 68.2-75.1), with CHARM scores stratifying survival to 81.2%, 73.8%, and 59.6% for low, intermediate, and high-risk tertiles. CHARM demonstrated higher net benefit than HCT-comorbidity index across a wide range of threshold probabilities for nonrelapse mortality. IN PRACTICE: 'The CHARM should improve decision-making [and] selection of the best transplant strategy by weighing risks vs benefits, allow calibration of data across trials and institutions, and ensure that appropriate older patients are not excluded from curative-intent allo-HCT,' wrote the authors of the study. SOURCE: The study was led by Mohamed L. Sorror, PhD, Clinical Research Division, Fred Hutchinson Cancer Center in Seattle, Washington. It was published online in Blood Advances. LIMITATIONS: The researchers acknowledged that the cross-validation bias-corrected area under the curve of 0.591 for primary-CHARM was modest, indicating room for improvement in predictive accuracy. The study's large sample size requirement and declining nonrelapse mortality made a parallel external validation cohort impractical. Additionally, the contribution from underrepresented minority groups was modest despite broad eligibility and supporting three languages. The study was conducted only in US centers, potentially limiting its global applicability. DISCLOSURES: The study received support from grants U10HL069294 and U24HL138660 to the Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung, and Blood Institute and the National Cancer Institute. Sorror reported receiving consultancy fees and honoraria from JAZZ Pharmaceuticals for educational talks and research funding from BlueNote. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Business Upturn
12 hours ago
- Business Upturn
BEL in focus: To manufacture defence missile system under ‘Project Kush'
By Aditya Bhagchandani Published on August 18, 2025, 15:20 IST Shares of Bharat Electronics Ltd (BEL) were in focus today, slipping marginally by 0.7% to ₹382.15 even as Zee Business reported that the company will play a lead role in Project Kush, a major defence programme for the Indian Army. According to the Zee Business report, BEL will be responsible for manufacturing a new-generation missile system, which will include four variants designed to strengthen India's defence capabilities. The trial of the first variant is expected to be completed within the next one year. Project Kush is seen as a critical step in enhancing India's indigenous defence production capabilities under the 'Make in India' and self-reliance initiatives. Analysts believe BEL's participation not only expands its order book visibility but also strengthens its long-term positioning as the country's leading defence electronics manufacturer. With a market cap of ₹2.80 lakh crore and an average daily volume of 12.6 million shares, BEL remains one of the most actively traded PSU defence counters. Market watchers say any formal announcements around Project Kush are likely to act as a significant trigger for the stock in the coming quarters. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
12 hours ago
- Business Upturn
Reliance Consumer Products forays into functional beverages with Shunya JV
By Aditya Bhagchandani Published on August 18, 2025, 15:43 IST Shares of Reliance Industries Ltd were in focus after its FMCG arm, Reliance Consumer Products Limited (RCPL), announced its entry into the healthy functional beverages space. The company has acquired a majority stake in a joint venture with Naturedge Beverages, the maker of herbal-infused zero-calorie brand Shunya. The move marks RCPL's next step toward building a complete beverage portfolio, expanding beyond Campa Cola, Campa Energy and Raskik. Through this JV, Reliance aims to leverage rising consumer demand for natural, herbal, and low-calorie functional drinks. Shunya, made with Ayurvedic super herbs such as Ashwagandha, Brahmi, Khus, Kokum and Green Tea, has already gained traction among health-conscious urban consumers. Management said the tie-up reinforces RCPL's goal of offering quality, affordable products while promoting India's Ayurvedic legacy. Ketan Mody, Executive Director of RCPL, highlighted that Shunya complements Reliance's beverage strategy and will soon see a wider rollout using Reliance's robust distribution network. Naturedge founder Siddhesh Sharma called the partnership a 'win-win,' noting that Reliance's reach will help transform Shunya into a pan-India brand at a time when demand for herbal-natural functional beverages is surging. With the addition of Shunya, RCPL plans to expand its lineup with energy shots, herb-infused water and other healthy alternatives, strengthening its positioning as a Total Beverage Company Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
